Tauopathies

Tauopathies are neurodegenerative disorders caused due to misfolding and aggregation of the tau protein in neurofibrillary tangles in the brain. Discover the latest research on tauopathies here.

June 25, 2020

Dual targeting of monomeric tau and α-synuclein aggregation: A new multitarget therapeutic strategy for neurodegeneration

ACS Chemical Neuroscience
Moustafa T Gabr, Francesca Peccati
July 9, 2020
Open Access

Testing Amyloid Cross-Toxicity in the Vertebrate Brain

ACS Omega
Gabriela HenríquezMahesh Narayan
July 3, 2020
Open Access

Increased Noradrenaline as an Additional Cerebrospinal Fluid Biomarker in PSP-Like Parkinsonism

Frontiers in Aging Neuroscience
Rocco CerroniRenato Massoud
July 2, 2020
Open Access

Insights into lncRNAs in Alzheimer's Disease Mechanisms

RNA Biology
Dingfeng LiQiang Liu
July 2, 2020

Excess tau PET ligand retention in elderly patients with major depressive disorder

Molecular Psychiatry
Sho MoriguchiMakoto Higuchi
July 6, 2020

In vivo positron emission tomography imaging of mitochondrial abnormalities in a mouse model of tauopathy

Neurobiology of Aging
Anna M BarronMakoto Higuchi
July 6, 2020

One stop shop: Flortaucipir PET differentiates amyloid positive and negative forms of neurodegenerative diseases

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
Jochen HammesThilo van Eimeren
July 1, 2020
Open Access

HspB5 Activates a Neuroprotective Glial Cell Response in Experimental Tauopathy

Frontiers in Neuroscience
David W HamptonSiddarthan Chandran
June 26, 2020
Review
Open Access

The Role of P2X7 Receptor in Alzheimer's Disease

Frontiers in Molecular Neuroscience
Linda FrancistiováMiguel Díaz-Hernández
July 6, 2020

Structures of the intrinsically disordered Aβ, tau and α-synuclein proteins in aqueous solution from computer simulations

Biophysical Chemistry
Phuong H Nguyen, Philippe Derreumaux
June 21, 2020

Chronic cannabidiol (CBD) treatment did not exhibit beneficial effects in 4-month-old male TAU58/2 transgenic mice

Pharmacology, Biochemistry, and Behavior
Georgia WattTim Karl
June 27, 2020

Targeting pathological tau by small molecule inhibition of the poly(A):MSUT2 RNA-protein interaction

ACS Chemical Neuroscience
Jeremy D BakerBrian C Kraemer
June 27, 2020
Open Access

Combination therapy with cilostazol, aripiprazole, and donepezil protects neuronal cells from β-amyloid neurotoxicity through synergistically enhanced SIRT1 expression

The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology
Hye Jin HeoChi Dae Kim
July 3, 2020
Open Access

Fyn kinase inhibition reduces protein aggregation, increases synapse density and improves memory in transgenic and traumatic Tauopathy

Acta Neuropathologica Communications
Si Jie TangStephen M Strittmatter
July 1, 2020

Inhibition of mTORC1 improves STZ-induced AD-like impairments in mice

Brain Research Bulletin
Yun CaoXinwen Zhou

Sign up to follow this feed and discover related papers.

Related Feeds

ALS

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS & FTD: TDP-43

ALS shares with a considerable proportion of FTD cases the same neuropathological substrate, namely, inclusions of abnormally phosphorylated protein tdp-43 (ptdp-43). Here are the latest discoveries pertaining to ptdp-43 and these diseases.

ALS - Pathogenic Mechanisms

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS - Phenotypes

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating phenotypes associated with this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here are the latest discoveries pertaining to this disease.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

Age-related Dementia

Age-related dementia (Alzheimer's disease) results from the destructive impact of the pulse on cerebral vasculature. Evidence is reviewed that the neuropathology of the dementia is caused by the breakdown of small cerebral vessels (silent microbleeds), that the microbleeds result from pulse-induced damage to the cerebral vessels, and that pulse becomes increasingly destructive with age, because of the age-related stiffening of the aorta and great arteries, which causes an increase in the intensity of the pressure pulse. Discover the latest research on age-related dementia here.

© 2020 Meta ULC. All rights reserved
/feed-previews/tauopathies/79cbac9b-3126-4814-a6b9-a83f020a462f